Currently, there are 43.35M common shares owned by the public and among those 33.22M shares have been available to trade.
The company’s stock has a 5-day price change of 0.49% and -29.95% over the past three months. It has a 12-month low price of $8.89 and touched a high of $24.50 over the same period. BBNX has an average intraday trading volume of 519.60K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 8.15%, 13.83%, and -7.16% respectively.
Institutional ownership of Beta Bionics Inc (NASDAQ: BBNX) shares accounts for 83.50% of the company’s 43.35M shares outstanding.
It has a market capitalization of $625.68M. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.94% over the week and 6.73% over the month.
Analysts forecast that Beta Bionics Inc (BBNX) will achieve an EPS of -0.5 for the current quarter, -0.46 for the next quarter and -2.2 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.7 while analysts give the company a high EPS estimate of -0.7. Earnings per share for the fiscal year are expected to increase by 73.76%, and 7.46% over the next financial year.
Looking at the support for the BBNX, a number of firms have released research notes about the stock. Stifel stated their Buy rating for the stock in a research note on February 24, 2025, with the firm’s price target at $25. Piper Sandler coverage for the Beta Bionics Inc (BBNX) stock in a research note released on February 24, 2025 offered a Overweight rating with a price target of $26. Leerink Partners was of a view on February 24, 2025 that the stock is Outperform, while Lake Street gave the stock Buy rating on February 24, 2025, issuing a price target of $30. BofA Securities on their part issued Buy rating on February 24, 2025.
